Back to search

Article

Hyperactive chemotaxis contributes to anti-TNFα treatment resistance in inflammatory bowel disease

2021-08-15

Abstract excerpt

<h4>Background & Aims</h4> Anti-tumour necrosis factor-alpha (anti-TNFα) agents have been used for inflammatory bowel disease (IBD), however, it has up to 30% non-response rate. Identifying molecular pathways and finding reliable diagnostic biomarkers for patient response to anti-TNFα treatment are clearly needed. <h4>Methods</h4> Publicly available transcriptomic data from IBD patients receiving anti-TNFα thera...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e48d2649-5b07-508e-9084-813250a3a7f4
DOI
10.1101/2021.08.15.456400
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Hyperactive chemotaxis contributes to anti-TNFα treatment resistance in inflammatory bowel diseaseDOI 10.1101/2021.08.15.456400
Integrated Gene Expression Profiling Analysis Reveals Probable Molecular Mechanism and Candidate Biomarker in Anti-TNFα Non-Response IBD PatientsSemantic proximity
The Clinical Response of Upadacitinib and Risankizumab is Associated with Reduced Inflammatory Bowel Disease Anti-TNFα Inadequate Response MechanismsSemantic proximity
Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in rheumatoid arthritis patientsSemantic proximity
Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn’s disease patientsSemantic proximity
Early Prediction of Clinical Response to Anti-TNF Treatment using Multi-omics and Machine Learning in Rheumatoid ArthritisSemantic proximity
The CCL2/CCR2 axis is related to primary non-response to infliximab therapy in patients with Crohn’s diseaseSemantic proximity
Molecular characterization of response to etrolizumab and anti-TNF reveals treatment resistance in ulcerative colitis is associated with an abundance of residual neutrophil subsets and inflammatory fibroblast populationsSemantic proximity
Biomarker Prediction and Immune Landscape of Angiogenesis in Inflammatory Bowel Disease: Insights from Bioinformatics and Machine Learning ApproachesSemantic proximity
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisSemantic proximity
Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico AnalysisSemantic proximity
Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling.Semantic proximity
Cytokine interaction networks, not individual cytokines, drive anti-TNF response in Crohn’s diseaseSemantic proximity
Select a neighboring publication to make it the new centre.